ClinicalTrials.gg
RecruitingNCT05979038Updated Sep 13, 2023

Clinical Evaluation of the Effect of Metformin in Sepsis

A Phase 3 interventional study of Metformin in Sepsis, sponsored by German University in Cairo. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by German University in Cairo · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Sepsis with a site in Egypt — 25 open to participants now, 27 under way, 3 of them phase 3. Sepsis · Egypt.

Planned enrollment
13th of 50
110 · median 80
Started
2023
with 18 others
Phase 3
5 of 106
2 open now
Primary completion
2024-06
later than 4 of 26 live
Registered
61st of 106
by date

Among the 106 studies in Sepsis with a site in Egypt, this one is the 13th largest by planned enrollment of the 50 interventional ones that give a count, is one of 19 that started in 2023, is one of 5 in phase 3, reaches primary completion later than 4 of the 26 other live ones, and was the 61st registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

25 of the 106 studies in Sepsis with a site in Egypt are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Sepsis with a site in Egypt, or all of them as a file.
02

Study summary

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. It is considered a condition that arises when the body's response to an infection injures its own tissues and organs. The pathogenesis of sepsis is very complicated as it involves imbalance in inflammatory response, immune dysfunction, mitochondrial damage, coagulopathy, neuroendocrine immune network abnormalities, endoplasmic reticulum stress, autophagy, and other pathophysiological processes, and leads to organ dysfunction. Inflammatory Imbalance represents the most critical basis of sepsis pathogenesis. Sepsis is associated with many biochemical abnormalities that is correlated with patients' prognosis and risk of mortality including increased levels of lactate, procalcitonin and inflammatory cytokines as TNF alpha.

Metformin is an oral anti-diabetic drug from the class of biguanides. It is the first line treatment of diabetes type 2. It is widely used as it has good safety profile, low side effect and cheap cost. Metformin has been reported to have an anti-inflammatory and anti-microbial effect.

Some studies have shown that metformin has a beneficial effect in sepsis patients. Our study will be the first prospective controlled randomized trial to assess the clinical outcome of metformin in patients with sepsis.

Read the detailed description

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. It is considered a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs (Singer et al., 2016a). Organ dysfunction can be defined as an increase in the Sequential (sepsis related) Organ Failure Assessment (SOFA) score more than two points consequent to the infection. A SOFA score more than two points indicates that an overall mortality risk of approximately 10% in hospital population with suspected infection.(Singer et al., 2016b). Septic shock is defined as subset of sepsis in which circulatory, cellular, and metabolic abnormalities are associated with a greater risk of mortality than sepsis alone. Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP (mean arterial pressure) more than or equal 65mmHg and having a serum lactate level >2 mmol/L (18mg/dL) despite adequate volume resuscitation (Seymour et al., 2016).

Sepsis and septic shock are major healthcare problems, affecting millions of people around the world each year with a mortality rate between one in three and one in six of those it affects (Evans et al., 2021). According to a meta-analysis conducted in 2020, it was found that the incidence of sepsis was 189 hospital-treated sepsis cases per 100,000 person-years with a 26.7% mortality rate. In ICU patients, the incidence was 58 per 100,000 person-years with a mortality rate of 41.9% prior to hospital discharge (Fleischmann-Struzek et al., 2020).

The pathogenesis of sepsis is very complicated as it involves imbalance in inflammatory response, immune dysfunction, mitochondrial damage, coagulopathy, neuroendocrine immune network abnormalities, endoplasmic reticulum stress, autophagy, and other pathophysiological processes, and leads to organ dysfunction. Inflammatory Imbalance represents the most critical basis of sepsis pathogenesis. The host's initial acute response to invasive pathogens causes macrophages to engulf the pathogens and produce a range of pro-inflammatory cytokines, and this can trigger cytokine storms and activate the innate immune system. The activation of the innate immune system is mediated by pattern-recognition receptors (PRRs), which initiate a series of activation in immune cells by detecting damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs), and thus upregulate the expression of inflammation related genes. In the immune response to sepsis, both exogenous factors derived from the pathogen (e.g., lipopolysaccharide (LPS)) and endogenous factors released by injured cells (e.g., high-mobility group box-1 (HMGB-1) protein) can interact with various PRRs, such as Toll-like receptors (TLRs), which leads to the activation of several pathways including p38 mitogen-activated protein kinase (MAPK), and nuclear factor-κB (NF-κB) signaling pathways. These events are followed by the production of inflammatory cytokines such as interleukin (IL)-1, IL-6, tumor necrosis factor-α (TNF-α), interferon (IFN) regulatory factor 7 (IRF7), and adaptor protein 1 (AP-1) (Huang, Cai and Su, 2019).

Moreover, studies have also shown that in early stages of sepsis, exaggerated endothelial activation, vascular leakage, disturbance of blood flow, as well as other derangements cause the loss of vascular integrity, which contributes significantly to sepsis-associated organ failure. Therapies interfering endothelial activation are potential to attenuate sepsis-induced organ dysfunction (Tian et al., 2019) Sepsis is associated with many biochemical abnormalities that is correlated with patients' prognosis and risk of mortality including increased levels of lactate, procalcitonin and inflammatory cytokines as TNF alpha.(Cho and Choi, 2014) Despite great efforts was done to understand the pathogenesis of sepsis and investigate therapeutic strategies, the management of sepsis remains a clinical challenge (Tian et al., 2019). Till current date the pathogenesis of sepsis is not completely clear but most of the studies suggested that the release of inflammatory factors by patient's innate immune cell plays an important role in the disease progression (Liang et al., 2019). Recently several studies revealed the anti-inflammatory effect of some drugs in sepsis. One of the drugs that showed anti-inflammatory effect in these studies is metformin (Han et al., 2018).

Metformin is an oral anti-diabetic drug from the class of biguanides. It is the first line treatment of diabetes type 2. It is widely used as it has good safety profile, low side effect and cheap cost (Malik et al., 2018). Studies have shown that metformin modulates cellular metabolism by two inter-related mechanisms. It transiently inhibits mitochondrial complex I of the electron transport chain, decreasing the production of mitochondrial reactive oxygen species and complex I inhibition also leads to an increase of the adenosine monophosphate/adenosine triphosphate (ATP) ratio (a critical signal of energy imbalance), which activates the AMPK. AMPK is a ubiquitous, critical cellular energy sensor with pleiotropic effects on cell metabolism, which can protect the cell by shutting down ATP consuming processes, promoting fatty acid oxidation and controlling the turn-over cycle of injured mitochondria. Metformin and AMPK activation improve endothelial function, reducing capillary leak and inducible nitric oxide synthase and increasing endothelial nitric oxide synthase activity potentially improving vascular tone and microvascular function (Gómez et al., 2022) Metformin has been reported to have an anti-inflammatory effect. In a prospective study to investigate the anti-inflammatory effect of AMPK activation in vivo, metformin and AICAR was administered respectively to mice prior to LPS injection. LPS injection significantly increased the level of VCAM1 in the arterioles, peritubular capillaries, post capillary venules, and glomerulus in the kidneys as well as in the arterioles, alveolar capillaries, and venules in the lungs. Metformin and AICAR administration effectively reduced VCAM1 expression in the microvascular beds both in the kidneys and lungs. Furthermore, LPS-induced increase of the serum levels of pro-inflammatory cytokines TNF⍺ and IL-6 were both significantly decreased by metformin and AICAR (Tian et al., 2019). In a trial of patients receiving glucocorticoid treatment for various chronic inflammatory diseases, 12 weeks of treatment with metformin 2550 mg/day resulted in lower serum levels of high-sensitive CRP as compared to placebo. Furthermore, carbohydrate-challenged TNF-α levels increased significantly in the placebo-treated group but not in the metformin-treated group (Pernicova et al., 2020) In addition, metformin showed some antibacterial activity. A retrospective study conducted in 2022 has shown that at the cellular level, metformin modulates cell metabolism through transient inhibition of complex I of mitochondrial electron transport chain and activates AMPK that protects energy balance in the cell (Gómez et al., 2022). It enhances neutrophil chemotaxis and phagocytosis and bacterial clearance (Bai and Chen, 2021).

Some studies have shown that metformin has a beneficial effect in sepsis patients. In two retrospective studies of septic shock patients receiving metformin, it showed an improvement in inflammatory response and oxidative stress induced by sepsis which resulted in improved mortality at different doses of metformin (Gras et al., 2006; Doenyas-Barak et al., 2015) . In a systematic review and meta-analysis done by Liang et al for published observational cohort data to determine the association between preadmission metformin use and mortality in septic adult patients with diabetes mellitus, it was concluded that preadmission metformin users had lower mortality than non-users and this analysis suggested that the effect of metformin is related to its anti-inflammatory effect (Liang et al., 2019).

Metformin has not significant adverse effects; however, it may cause gastrointestinal upset that can be overcome by titration of the dose and administration with meals (Nasri and Rafieian-Kopaei, 2014) and a rare but serious condition called lactic acidosis with the following symptoms: dizziness, severe drowsiness, muscle pain, tiredness, chills, blue/cold skin, fast/difficult breathing, slow/irregular heartbeat, stomach pain with diarrhea, nausea or vomiting. Lactic acidosis usually occurs due to drug overdose or in some contraindicated conditions (Scheen and Paquot, 2013). Rare incidence of lactic acidosis has been reported with the use of metformin especially in patients with renal impairment, hence, metformin is contraindicated in those with creatinine clearance less than 45ml/min. In sepsis, previous study reported that patients hospitalized for suspected sepsis who were on metformin had slightly higher prevalence of hyperlactatemia than non- metformin users though non-metformin users were found to have a higher 28-days mortality risk than metformin users (Green et al., 2012). In another study, conducted to compare the prognosis of extremely elevated plasma lactate levels and septic shock between metformin users and non-users it was found that the rate of in hospital mortality was lower for those who were actively treated with metformin than those who were not. the prognosis of metformin users were better despite higher lactate levels (Doenyas-Barak et al., 2015). One last study was done to evaluate the impact of metformin use on lactate kinetics in septic patients and showed that lactate levels in metformin users were initially elevated in the early phase in severe sepsis and septic shock. However, there was no significant difference in lactate levels, lactate clearance and normalization over the initial 24 hours period based on metformin use (Park et al., 2017)

To the best of our knowledge our study will be the first prospective controlled randomized trial to assess the clinical outcome of metformin in patients with sepsis.

03

Conditions studied

  • Sepsis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age more than 18 years old.
  • A diagnosis of sepsis according to the latest Sepsis-3 definition
  • Estimated >45 ml/min

Exclusion criteria

Exclusion Criteria:

    • or end stage cancer.

      • Septic Shock.
      • Pregnancy and breast feeding.
      • Patients on metformin, Sodium glucose cotransporters or Gliptins.
      • End stage hepatic disease.
      • to metformin (chronic respiratory failure, chronic cardiac failure, chronic kidney or liver disease, myocardial infarction within the last month).
      • Patients with to metformin.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Metformin arm

    In this arm patients will administrate metformin 500 mg three times a day together with the standard care of sepsis.

    Drug: Metformin

  • No intervention
    Control Arm

    In this arm patients will receive the standard care of sepsis only

Interventions

  • Patients in the intervention arm will take metformin 500mg three times a day

    Also known as: Glucophage

06

What researchers measure

Primary outcomes

  1. 28 days mortality

    Patients mortality rate and time from ICU admission till death due to any cause will be assessed within 28 days even after discharge from the ICU.

    Time frame: 28 days

Secondary outcomes

  1. 2.Total ICU lengths of stay:

    The number of days that the patient will stay in the ICU will be calculated.

    Time frame: 28 days

  2. 3.Arterial blood gases (ABG):

    ABG will be measured daily for every patient throughout his/her stay in the ICU. The total number of days that ABG are abnormal will be calculated for every patients in order to get the number of abnormal readings and check after how long ABG returned to normal

    Time frame: 28 days

  3. 4- Serum TNF alpha:

    Blood samples will be withdrawn at baseline and day ten of ICU admission from every patient included in the study to measure TNF alpha. Samples will be stored in -80C and will be assessed using ELISA technique.

    Time frame: 28 days

  4. 5- Total Leucocytic Count (TLC):

    Blood samples will be withdrawn daily from every patient included in the study to measure TLC. The total number of days that TLC is high will be calculated for every patients in order to get the number of abnormal readings and check after how long TLC returned to normal ( 4000 to 11,000/microliters).

    Time frame: 28 days

  5. 6- Sequential organ Failure assessment Scores (SOFA):

    SOFA score will be calculated daily for every patient to assess organ failure and recovery. Sequential Organ Failure Assessment score (SOFA) is a scoring system used to evaluate organ failure. The score is based on six different scores: respiratory, cardiovascular, hepatic, coagulation, renal and neurological system. It calculates the degree of organ failure by assigning a point of 0 (normal) to 4 (failure) for each organ. Score ranges from 0 (best) to 24 (worst) points. For calculating SOFA score the below table 1 will be used:(Singer et al., 2016a)

    Time frame: 28 days

  6. 7- APACHE II Score:

    APACH II score will be calculated daily for every patient to assess disease severity. The score can help in the assessment of patients to determine the level \& degree of diagnostic \& therapeutic intervention. Score ranges from minimum 0 and maximum 71; increasing score is associated with an increasing risk of hospital death. For calculating APACHE score, below table will be used (Akavipat, 2019)

    Time frame: 28 days

  7. 8-GCS Score:

    Glasgow Coma scale (GCS) will be calculated daily to assess patient's consciousness. It is scored between 3 and 15, with 3 being the worst and 15 the best. It is composed of 3 parameters: best eye response (E), best verbal response (V), and best motor response (M). A score of 13 or higher correlates with mild brain injury, a score of 9 to 12 correlates with moderate injury, and a score of 8 or less represents severe brain injury (Teasdale and Jennett, 1974).

    Time frame: 28 days

  8. 9-28 days Readmission:

    The number of patients who were discharged from the ICU and returned again within 28 days will be calculated

    Time frame: 28 days

  9. 10-Blood Pressure

    All patients included in the study will be monitored 24 hours a day (24/24) by putting them on a vital signs monitor in order to follow up their blood pressure. The total number of abnormal blood pressure measurements will be calculated for every patient. Mean arterial blood pressure will also be calculated (target is 65 mm Hg) and the total number of days patient will need a vasopressor will be calculated and doses of vasopressor will be documented.

    Time frame: 28 days

  10. 11-Mechanical Ventilation:

    Number of patients who will need mechanical ventilation will be calculated. In addition, ventilation free days will be assessed for every patient.

    Time frame: 28 days

  11. 12-Serum Lactate levels:

    Blood samples will be withdrawn every other day from every patient included in the study to measure serum lactate levels. The lactate cutoffs determining an elevated level ranged from 1.6-2.5 mmol/L (Evans et al., 2021). Patients with elevated serum lactate levels will be closely monitored. The number of days that serum lactate levels are high will be calculated for every patient throughout the study

    Time frame: 28 days

  12. GIT Disturbances:

    Patient will be interviewed for the incidence of nausea, vomiting or diarrhea. If patient cannot reply (low conscious level), nurses will be asked. The total number of days that patient will suffer any of the GIT disturbances will be calculated and documented.

    Time frame: 28 days

07

Study locations

1 of 1 sites recruiting
  • Al Demerdash University Hospital
    Cairo, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jun 2024, 9 months after the start.

Of 58 non-industry phase 3 interventional studies under Sepsis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 9 months is below that.

Counting every sponsor, half of 66 studies reached it within 39 months; a quarter within 24 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2023
First posted
Aug 7, 2023
StartActual
Sep 10, 2023
Primary completionEst.
Jun 15, 2024
CompletionEst.
Jul 10, 2024
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05979038
Lead sponsor
German University in Cairo
Responsible party
Mai Tarek Ghannoum (Assistant Lecturer of Clinical Pharmacy, German University in Cairo) — Principal investigator
First posted
Aug 7, 2023
Start date
Sep 10, 2023
Primary completion
Jun 15, 2024 (estimated)
Completion
Jul 10, 2024 (estimated)
Last update
Sep 13, 2023

Study contacts

Mai M.T Ghannoum, Assistant Lecturer
Contact
mai.tarek@guc.edu.eg
002-01221054807
Mohamed H. Solayman, Lecturer
Contact
mohamed.solayman@guc.edu.eg
002-01005882550

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion